Reference : Le medicament du mois. Valdecoxib (Bextra)
Scientific journals : Article
Human health sciences : Rheumatology
Human health sciences : Pharmacy, pharmacology & toxicology
Le medicament du mois. Valdecoxib (Bextra)
[en] Valdecoxib (Bextra)
Scheen, André mailto [Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale >]
Malaise, Michel mailto [Centre Hospitalier Universitaire de Liège - CHU > > Rhumatologie >]
Revue Médicale de Liège
Yes (verified by ORBi)
[en] Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/therapeutic use ; Arthritis, Rheumatoid/drug therapy ; Cyclooxygenase Inhibitors/administration & dosage/therapeutic use ; Dysmenorrhea/drug therapy ; Enzyme Inhibitors/administration & dosage/therapeutic use ; Female ; Humans ; Infusions, Intravenous ; Injections, Intramuscular ; Isoxazoles/administration & dosage/therapeutic use ; Osteoarthritis/drug therapy ; Pain, Postoperative/drug therapy ; Prodrugs ; Sulfonamides/administration & dosage/therapeutic use
[en] Valdecoxib (Bextra tablets of 10 mg and 20 mg) is a new non steroidal antiinflammatory drug (NSAID) that selectively inhibits COX-2 isoform of cyclo-oxygenase. It is indicated for the symptomatic treatment of osteoarthritis or rheumatoid arthritis (10 to 20 mg once a day) and for the treatment of primary dysmenorrhea (40 mg once a day). Valdecoxib is as efficacious as conventional non-COX-2 selective NSAIDs, but offers the advantage of a much better gastrointestinal tolerance. Valdecoxib has a prodrug that can be administered intravenously or intramuscularly (parecoxib, Dynastat) and has been developed for the short-term treatment of postsurgical pain.
Researchers ; Professionals

File(s) associated to this reference

Fulltext file(s):

Open access
200404_17.pdfNo commentaryPublisher postprint448.48 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.